United States: FDA User Fee Reauthorization Legislation Continues To Simmer In Congress: What's At Stake And What It Means For September - Akin Gump Strauss Hauer & Feld LLP

As outlined in Akin Gump's previous analysis, the current five-year authorization of the Food and Drug Administration (FDA) user fee programs for branded/reference drugs and biologics...